menu

CME: Gasping for Air: Asthma Heterogeneity & What It Means for Your Patients

Be part of the knowledge.™
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

How to ID Patients with Difficult-to-Control Asthma

close
ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Media formats available:
Details
Presenters
Related
Comments

  • Overview

    Please note:This activity is no longer available for continuing education credit. 

    Understanding the mechanisms of disease has dramatically shifted our therapeutic strategies and methods of patient stratification when treating asthma. The advent of new clinical biomarkers, differential understanding of phenotypes and endotypes, and the introduction of biologics has come with questions of patient selection and suitability for novel treatment strategies. This activity combines the powerful impact of artistic design, infographic presentation, and scientific expertise to deliver the latest in asthma pathophysiology, disease heterogeneity, and biomarker understanding to help inform optimal treatment selection. 

  • Provider

    ReachMD Healthcare ImageReachMD Healthcare Image

  • Faculty

    Bradley E. Chipps, MD, FAAP, FACAAI, FAAAAI, FCCP
    Past-President, American College of Allergy, Asthma & Immunology
    Medical Director, Capital Allergy & Respiratory Disease Center
    Sacramento, CA 

  • Conflict of Interest Policy/Disclosure Statement

    The Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

    Bradley E. Chipps, MD, FAAP, FACAAI, FAAAAI, FCCP, has affiliations with AstraZeneca, Boehringer Ingelheim, Circassia, Genentech, Novartis, Regeneron, Sanofi, Teva Pharmaceutical Industries Ltd. (Consulting); AstraZeneca, Boehringer Ingelheim, Circassia, Genentech, Novartis, Regeneron, Sanofi, Teva Pharmaceutical Industries Ltd. (Other Speakers Bureau)

    Planners and Managers
    The PIM planners and managers have nothing to disclose. RMEI Medical Education, LLC planners and managers have nothing to disclose.

  • Target Audience

    The target audience for this activity is pulmonary and allergy/immunology providers including physicians, nurse practitioners, and physician assistants who manage patients with asthma. 

  • Learning Objectives

    1. Distinguish between the different types of asthma based on underlying pathophysiology and biomarkers of disease in order to make personalized treatment decisions 

    2. Identify patients with poorly controlled or difficult-to-treat asthma who are eligible for step up therapies, including new and emerging biologics 

  • Joint Accreditation Statement

    ReachMD Healthcare Image

    In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Media: Internet 

  • Commercial Support

    This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • How to Receive Credit

    By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and PAs are entitled to receive up to 0.5 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print immediately. Users must:

    • Read the learning objectives and faculty disclosures.
    • Participate in the activity.
    • Complete the activity evaluation.

    Physicians, nurse practitioners, and PAs who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. If you would like to contact Postgraduate Institute for Medicine, please email inquiries@pimed.com.

  • Publication Dates

    Release Date: 

    End Date: This activity is no longer available for continuing education credit. 

Presenters

Related

Facebook Comments

Recommended
Details
Presenters
Related
Comments

Recommended

  • Overview

    Please note:This activity is no longer available for continuing education credit. 

    Understanding the mechanisms of disease has dramatically shifted our therapeutic strategies and methods of patient stratification when treating asthma. The advent of new clinical biomarkers, differential understanding of phenotypes and endotypes, and the introduction of biologics has come with questions of patient selection and suitability for novel treatment strategies. This activity combines the powerful impact of artistic design, infographic presentation, and scientific expertise to deliver the latest in asthma pathophysiology, disease heterogeneity, and biomarker understanding to help inform optimal treatment selection. 

  • Provider

    ReachMD Healthcare ImageReachMD Healthcare Image

  • Faculty

    Bradley E. Chipps, MD, FAAP, FACAAI, FAAAAI, FCCP
    Past-President, American College of Allergy, Asthma & Immunology
    Medical Director, Capital Allergy & Respiratory Disease Center
    Sacramento, CA 

  • Conflict of Interest Policy/Disclosure Statement

    The Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

    Bradley E. Chipps, MD, FAAP, FACAAI, FAAAAI, FCCP, has affiliations with AstraZeneca, Boehringer Ingelheim, Circassia, Genentech, Novartis, Regeneron, Sanofi, Teva Pharmaceutical Industries Ltd. (Consulting); AstraZeneca, Boehringer Ingelheim, Circassia, Genentech, Novartis, Regeneron, Sanofi, Teva Pharmaceutical Industries Ltd. (Other Speakers Bureau)

    Planners and Managers
    The PIM planners and managers have nothing to disclose. RMEI Medical Education, LLC planners and managers have nothing to disclose.

  • Target Audience

    The target audience for this activity is pulmonary and allergy/immunology providers including physicians, nurse practitioners, and physician assistants who manage patients with asthma. 

  • Learning Objectives

    1. Distinguish between the different types of asthma based on underlying pathophysiology and biomarkers of disease in order to make personalized treatment decisions 

    2. Identify patients with poorly controlled or difficult-to-treat asthma who are eligible for step up therapies, including new and emerging biologics 

  • Joint Accreditation Statement

    ReachMD Healthcare Image

    In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Media: Internet 

  • Commercial Support

    This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • How to Receive Credit

    By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and PAs are entitled to receive up to 0.5 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print immediately. Users must:

    • Read the learning objectives and faculty disclosures.
    • Participate in the activity.
    • Complete the activity evaluation.

    Physicians, nurse practitioners, and PAs who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. If you would like to contact Postgraduate Institute for Medicine, please email inquiries@pimed.com.

  • Publication Dates

    Release Date: 

    End Date: This activity is no longer available for continuing education credit. 

Presenters

Related

Facebook Comments

PrevNext
Programs 9/25/21

    Segment Chapters

    Playlist:

    Recommended